Bristol Meyers Squibb It has brought to Spain a pioneer initiative that combines innovation in technology with AI to Improve the clinical monitoring of patients with hypertrophic myocardiopathy (MCH). The project, developed with the technology provider Tucuviis already in operation in the Vigen hospitals of the Arrixaca of Murcia, and Severo Ochoa in Madrid.
The project aims to reduce the clinical load associated with the monitoring of patients with an automated call system managed by a Virtual Clinical Assistant based on AI, which they have called Lola. In the calls made, patients answer several questions about their symptoms, collected in a validated questionnaire: Hypertrophic Cardiomyopathy Symptom Questionnaire.
The disease that both companies have joined to facilitate their treatment through technology, MCH, is cardiovascular and has hereditary origin. At present it is believed that it affects 1 in 500 adults, although it is believed that many cases are without diagnosing, and is seen as one of the main causes of sudden death in children under 35 years.
In its obstructive form, which add up to approximately 66% of cases, the hypertrophy of the heart can block blood output to the aorta, with symptoms such as dyspnea, chest pain, palpitations or syncope. Therefore, it has a lot of physical and emotional impact on the life of customers.
With the Lola assistant, the program allows a periodic and personalized remote monitoring of patients, without the need for specific devices or Internet connection, something very useful in isolated areas with less ease to access medical care.
The project will be carried out until September 2027, and there is a forecast to expand its implementation to new hospitals after evaluating the results obtained in this first phase. All with the aim of offering advanced and personalized solutions to patients with complex cardiovascular pathologies.
According to him Doctor Juan Ramón Gimeno, from the Virgen de la Arrixaca University Hospital«the Program implementation has been very simple, and the degree of satisfaction of the 52 patients who have been contacted so far, is high, with an average of 81 % in scope and 87 % in adhesion. Patients appreciate the control provided by Lola, a tool that facilitates narrow and automated monitoring thanks to which 5 clinical alerts that have allowed acting early have been detected and categorized before possible decompensation signs. For us, as professionals, having this real -time clinical information helps us anticipate and adjust the treatments more efficiently ».
By Bristol Meyers Squibb, José Manuel Fernández, Director of Strategy and Operations of the Company in Spain and Portugalstressed that in the company they believe «in the power of collaboration and technology to transform the lives of patients. This project exemplifies how innovation, applied with purpose, can relieve care load, empower medical equipment and, above all, improve the day -to -day life of people with chronic diseases such as hypertrophic myocardiopathy ».
As to María González, CEO and co -founder of Tucuvihas stressed that its technology «It allows to release time to clinical equipment while improving the patient’s experience. We are very proud to be able to collaborate with BMS and with public hospitals in a project that demonstrates how AI can have a real and positive impact on health care ».
